Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission
<p><strong>Background</strong> Tofacitinib is an oral, small-molecule JAK inhibitor approved in several countries for the treatment of ulcerative colitis (UC). Safety and efficacy of tofacitinib 5 and 10 mg twice daily (BID) were evaluated in 2 Phase 3 induction studies (OCTAVE Ind...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
Oxford University Press
2019
|